Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pamapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 13/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 11/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 4/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 3/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 3/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 1.00 |
| ▸ | NLK | Q9UBE8 | 2/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.64 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.64 |
| ▸ | GAK | O14976 | 1/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.60 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.60 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.60 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.60 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamapimod SCHEMBL3636701 | 1.00 | MAPK14 (1.00) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| Pamapimod SCHEMBL29379723 | 1.00 | MAPK14 (1.00) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL13239772 | 0.96 | MAPK14 (0.93) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL14014670 | 0.90 | MAPK14 (0.88) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL13239781 | 0.90 | MAPK14 (0.82) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL13239775 | 0.88 | MAPK14 (0.84) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL13239778 | 0.88 | MAPK14 (0.84) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL2944570 | 0.87 | MAPK14 (0.77) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL2944573 | 0.87 | MAPK14 (0.77) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL13239789 | 0.86 | MAPK14 (1.00) | MAPK14MAPK8MAPK11MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115105601-A | Pharmaceutical combination for the treatment of cancer | 投资支持有限公司 | 2022-09-27 | — | — | CN | claimed |
| CN-109414506-B | Pharmaceutical combination for the treatment of cancer | 投资支持有限公司 | 2022-06-03 | — | — | CN | claimed |
| EP-4648772-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2025-11-19 | — | — | EP | disclosed |
| US-20240344033-A1 | ENDOMETRIAL MODEL, METHOD FOR PREPARING ENDOMETRIAL MODEL, AND ENDOMETRIAL IMPLANTATION MODEL | TOHOKU UNIVERSITY (JP) | 2024-10-17 | — | — | US | disclosed |
| CN-114748622-B | P38 kinase inhibitors reduce DUX4 and downstream gene expression and treat FSHD | 弗尔康医疗公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-114732910-B | P38 kinase inhibitors reduce DUX4 and downstream gene expression and treat FSHD | 弗尔康医疗公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2024150014-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2024-07-18 | — | — | WO | disclosed |
| CN-118318033-A | Cell aggregate comprising pituitary hormone-producing cells and method for producing the same | 住友制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| EP-4390899-A1 | ENDOMETRIUM MODEL, METHOD FOR PRODUCING ENDOMETRIUM MODEL, AND ENDOMETRIAL IMPLANTATION MODEL | Tohoku University (JP) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023021591-A1 | ENDOMETRIUM MODEL, METHOD FOR PRODUCING ENDOMETRIUM MODEL, AND ENDOMETRIAL IMPLANTATION MODEL | 国立大学法人東北大学 | 2023-02-23 | — | — | WO | disclosed |
| WO-2023277135-A1 | METHOD FOR PRODUCING CELLS CONSTITUTING NASAL EPITHELIUM, AND CELL POPULATION INCLUDING CELLS CONSTITUTING NASAL EPITHELIUM OR PROGENITOR CELLS THEREOF | 住友化学株式会社 | 2023-01-05 | — | — | WO | disclosed |
| CN-115105601-A | Pharmaceutical combination for the treatment of cancer | 投资支持有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-109415680-B | Cell culture medium for organoid culture, culture method, and organoid | 学校法人庆应义塾 | 2022-08-16 | — | — | CN | disclosed |
| CN-114748622-A | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | 弗尔康医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114732910-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114650818-A | Casein kinase 1 inhibitors for the treatment of diseases associated with DUX4 expression such as muscular dystrophy and cancer | FACIO知识产权有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-109414506-B | Pharmaceutical combination for the treatment of cancer | 投资支持有限公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3982955-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | Facio Intellectual Property B.V. (NL) | 2022-04-20 | — | — | EP | disclosed |
| CN-111601593-B | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-109072179-B | Cell culture medium, culture method and organoid | 学校法人庆应义塾 | 2022-04-01 | — | — | CN | disclosed |